Targretin capsules — CareFirst (Caremark)
subcutaneous panniculitis-like T-cell lymphoma
Initial criteria
- Authorization may be granted for treatment as a single agent or in combination with prednisone.
Reauthorization criteria
- Authorization may be granted if no evidence of unacceptable toxicity or disease progression while on current regimen.
Approval duration
12 months